Skip to main content
ArticleOPEN ACCESS

CXCR3 blockade: a novel anti-sepsis approach?

Critical Care
DOI: 10.1186/cc11818
2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Blockade of the CXC chemokine receptor 3 (CXCR3) attenuates inflammation and improves survival in a murine model of near lethal polymicrobial sepsis. However, given the multitude of cellular responses and inflammatory mediators that orchestrate sepsis syndrome, more detailed investigations will be required before a complete understanding of the mechanism(s) of CXCR3 blockade and its therapeutic potential are revealed. © 2012 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Delano, M. J., & Moldawer, L. L. (2012, November 21). CXCR3 blockade: a novel anti-sepsis approach? Critical Care. https://doi.org/10.1186/cc11818

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free